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Abstract
Lipophilic cationic technetium-99m-complexes are widely used for myocardial perfusion imaging (MPI). However, inherent
uncertainties in the supply chain of molybdenum-99, the parent isotope required for manufacturing 99Mo/99mTc generators,
intensifies the need for discovery of novel MPI agents incorporating alternative radionuclides. Recently, germanium/gallium
(Ge/Ga) generators capable of producing high quality 68Ga, an isotope with excellent emission characteristics for clinical PET
imaging, have emerged. Herein, we report a novel 68Ga-complex identified through mechanism-based cell screening that
holds promise as a generator-produced radiopharmaceutical for PET MPI.
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security, alternative production methodologies for Mo and Tc
have been sought [8]. A notable recent advance has been the high
yield direct production of 99mTc by proton-bombardment of
100
Mo using a conventional medical cyclotron [8]. Although
commercialization of these methodologies could substantially
lower overall dependence upon enriched uranium and security
concerns associated with handling of processed nuclear waste, the
high costs of various alternative production strategies complicate
medical reimbursement models. Thus, there is need for novel MPI
agents derived from alternative radionuclides, particularly agents
incorporating isotopes compatible with positron emission tomography (PET) imaging, a technology with superior spatial and
temporal resolution compared to SPECT [2,9].
MPI agents based on flourine-18 (18F; tK = 110 min), a
common cyclotron-produced PET isotope, have been reported
[10,11], but 18F-based agents depend on the presence of nearby
cyclotrons, which place constraints on isotope distribution logistics.
Another PET MPI agent is rubidium-82 chloride (tK = 75 sec),
obtained via electron capture from strontium-82 (tK = 25 d), but
the high cost and short half-life of this generator-produced isotope
limit its utility. Recently, germanium/gallium (Ge/Ga) generators
capable of producing high quality 68Ga (tK = 68 min), an isotope
with excellent emission properties for clinical PET imaging [12],
have emerged. The parent isotope, 68Ge (tK = 271 days), is
produced in high energy proton accelerators from a 69
Ga(p,2n)68Ge reaction and is bonded to alumina for eventual
elution on-site [13], thus providing a practical generatorbased distribution model for on-site formulation of PET

Introduction
Cardiovascular disease remains the leading cause of death in
developed countries as well as in most developing countries [1].
Myocardial perfusion imaging (MPI), a non-invasive measure of
blood flow in the heart, is commonly used to determine areas of
reversible ischemia, characterize infarcted tissue, and assess left
ventricular function [2]. Currently, single photon emission
computed tomography (SPECT) imaging with the radioactive
transition metal technetium-99m (99mTc; tK = 6.2 hrs) incorporated into monocationic complexes (e.g., 99mTc-sestamibi, 99mTctetrofosmin) is widely used [2,3]. Following intravenous injection,
these 99mTc-complexes distribute into heart tissue in proportion to
blood flow and remain trapped for times sufficient to image
perfusion territories. Molybdenum-99 (99Mo; tK = 66 hrs), the
parent isotope of 99mTc, is produced by nuclear fission in reactors
from enriched uranium-235, and is packaged into 99Mo/99mTc
generators for distribution to nuclear pharmacies. This production
and distribution model is convenient, cost effective, and has
provided on-site formulation advantages for decades. However,
there are only five active production reactors in the world [4,5],
and healthcare disruptions during the 99Mo/99mTc crisis of 2008–
2010, in which only two reactors were on-line [6], demonstrated
the vulnerability of the world supply of 99Mo. Furthermore,
proposals for upgrades of these reactors are relatively expensive,
and security concerns have been raised for the continued
dependence on a technology requiring enriched uranium fuel
[7]. To address these shortcomings in the supply chain and
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radiopharmaceuticals. With co-development of high quality 68Gabased tracers, PET imaging could be unlinked from proximity to
cyclotrons, thereby expanding access to the technology. A variety
of synthetic cationic complexes of Ga(III) have been reported as
candidate 68Ga PET tracers [14–23]; however, identification of a
68
Ga-complex with biochemical and pharmacokinetic properties
ideally suited for PET MPI has proven elusive.

water containing 0.1% formic acid and analyzed via HRESI.
Elemental analyses were performed by Galbraith Laboratories,
Knoxville, TN. HPLC analysis was performed with a Waters
System 600 equipped with dual l-detector 2487 (set to 280 and
214 nm) and a c-detector (Bioscan) for identification of radiopeaks. Gallium(III) complex 4 and its radiolabeled analogues 5a
and 5b were assessed for purity on a C-18 reversed-phase column
(Vydac TP, 10 mm, 300 Å) using an eluent gradient of ethanol and
saline (isocratic 20% ethanol in saline for 5 min; gradient from
20% to 90% ethanol in saline from 5–40 min, at a flow of 2 mL/
min). Radiochemical purity was determined on C-18 plates
employing a mobile eluent mixture of 90% ethanol in saline,
using a radio-TLC (Bioscan System 200 Image Scanner).
Metabolite analysis was performed using radio-TLC (Bioscan
System 200 Image Scanner).

Materials and Methods
General Methods
All reagents were purchased from Sigma-Aldrich unless
otherwise stated. The linear tetramine, 1,2-ethylenediaminobis(2,2-dimethylaminopropane) was synthesized as described
previously [20]. 1H NMR and proton-decoupled 13C NMR
spectra were recorded on either a Varian (300 MHz) or Bruker
(400 MHz) spectrometer; chemical shifts are reported in d (ppm)
with reference to TMS. Mass spectra were obtained from the
Washington University Resource for Biomedical and Bioorganic
Mass Spectrometry using samples diluted in 50/50 methanol/

Chemical Synthesis
2-hydroxy-3-isopropoxy-benzaldehyde (2). 2-isopropoxyphenol 1 (1.34 mmol), anhydrous magnesium chloride
(6.73 mmol), and anhydrous triethylamine (13.4 mmol) were
suspended in anhydrous acetonitrile (50 mL), and the suspension
stirred for 1 h at room temperature. Then, p-formaldehyde
(6.72 mmol) was added to the mixture and the contents were
heated at reflux for 4 h. The reaction mixture was cooled to room
temperature, hydrolyzed, acidified with 10% HCl (50 mL), and
extracted with ether (36200 mL). The combined organic extract
was dried over anhydrous sodium sulfate, filtered, concentrated,
and the residue was purified on silica gel GF254 (Analtech, USA)
using a hexane/ethyl acetate (70/30) eluent mixture; 57% yield.
1
H NMR (300 MHz, CDCl3) d: 1.38 (d, 6H), 4.58 (sept, 1H), 6.93
(t, 1H), 7.13–7.20 (dd, 2H), 9.91 (s, 1H), 10.97 (s, 1H); 13C NMR
(75 MHz, CDCl3) d: 22.3, 72.4, 119.8, 121.6, 123.1, 125.5, 146.7,
153.2, 196.7; MS(HRESI) Calcd for [C10H12O3]+: 163.0754;
found: 163.0759.
3,39-(2-hydroxy-3-isopropoxyphenylimidazolidine-1,3-diyl)
bis[1-{(2-hydroxy-3-isopropoxyphenyl)methyleneamino-2,2dimethyl}propane] (3). To obtain 3, starting precursors, 2-

hydroxy-3-isopropoxy-1-benzaldehyde 2 (2.7 mmol) and 1,2-ethylenediamino-bis(2,2-dimethylaminopropane) (0.90 mmol) were dissolved in ethanol (10 mL), refluxed for 45 min, and purified by
methods described previously [20,22]. 1H NMR (400 MHz,
CDCl3) d: 0.79 (s, 12H), 1.27 (d, 6H), 1.36 (d, 12H), 2.27 (d, 2H),
2.52 (d, 2H), 2.64 (s, 2H), 3.0 (d, 2H), 3.38 (d, 2H), 3.50 (d, 2H) 3.74
(s, 1H), 4.40 (sept, 1H), 4.55 (sept, 2H), 6.60 (br, d, 2H), 6.71–6.90
(m, 7H), 8.05 (s, 2H), 10.20 (s, 1H), 13.9 (s, 2H); 13C NMR (100
MHz, CDCl3) d: 22.3, 22.4, 24.6, 24.8, 36.7, 54.6, 62.6, 68.1, 71.2,
72.3, 91.8, 117.6, 118.1, 118.3, 119.2, 119.6, 123.6, 124.7, 146.2,
146.6, 149.7, 153.5, 165.5. MS(HRESI), Calcd for [C42H60N4O6]:
716.4513; found: [M+H]+717.4598.
(1,2-ethylenediamino-bis[1-{(3-isopropoxyphenyl-2-ate)
methyleneamino-2,2-dimethyl}-propane]gallium(III))iodide
[ENBDMP-3-isopropoxy-PI-Ga]+ I2 (4). The ligand 3

(100 mg, 0.18 mmol) dissolved in methanol (5 mL) was treated
with dropwise addition of gallium(III) acetylacetonate (66.2 mg,
0.18 mmol) dissolved in methanol. The contents were refluxed for
3 h. Then, potassium iodide (30 mg, 0.18 mmol) dissolved in hot
water (0.5 mL) was added and the reaction mixture was refluxed
further for 15 min, brought to room temperature slowly, and slow
evaporation over several days yielded crystalline material; 30%
yield. 1H NMR (300 MHz, DMSO-d6) d: 0.79 (s, 6H), 0.96 (s, 6H),
1.30–1.33 (dd, 12H), 2.63 (d, 2H), 2.79 (d, 4H), 2.94 (br, s, 2H),
3.61–3.75 (m, 4H), 4.63 (sept, 2H), 4.79 (br, s, 2H), 6.62 (t, 2H), 6.87
(d, 2H), 7.04 (d, 2H), 8.18 (s, 2H); 13C NMR (300 MHz, DMSO-d6)
d: 22.0, 22.1, 22.2, 26.2, 35.6, 47.7, 59.2, 68.9, 69.5, 115.7, 119.2,

Figure 1. Scheme for chemical synthesis of gallium(III)
complexes (4, 5a, and 5b).
doi:10.1371/journal.pone.0109361.g001
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Figure 2. Projection view of the cationic gallium(III) complex Ga-[3-isopropoxy-ENBDMPI]+ (4), with the iodide (I2) counteranion,
showing the crystallographic numbering scheme.
doi:10.1371/journal.pone.0109361.g002

Thereafter, HEPES buffer (pH 5.45, 400 mL) was added to the
eluent mixture, the pH was adjusted to 4.5, mixed with the ligand
solution, and heated at 100uC for 40 min. Reactions were followed
using thin-layer chromatography plates (C-18) employing a
radiometric scanner (Bioscan), using an eluent mixture of
ethanol/saline (90/10; Rf: 0.23). Finally, 67Ga-metalloprobe 5a
was purified by radio-HPLC on a C-18 reversed-phase column
(Vydac TP, 10 mm, 300 Å), using the gradient eluent mixture of
ethanol and saline described above. The fraction eluting at a
retention time of 27.0 min (5a) was collected, concentrated, and
employed for bioassays.
Preparation of 68Ga-metalloprobe (5b). Radiolabeled
68
Ga-metalloprobe (5b) was synthesized by following a procedure
described previously with slight modifications [21,22,24]. 68Ga
was obtained from a generator (Eckert & Ziegler Eurotope) as its
chloride salt, converted into 68Ga(acetylacetonate)3 by reacting
with acetylacetone (0.01% solution in ethanol) using standard
procedures. The radiolabeled 68Ga-metalloprobe was obtained
through a ligand exchange reaction involving 68Ga(acetylaceto-

119.5, 125.8, 148.7, 158.1, 170.3. MS(HRESI) Calcd for
[C32H48N4O4Ga]+: 621.2926, found: m/z = 621.2930; and Calcd
for [13C32H48N4O4Ga]+: 622.2959, found: m/z = 622.2967. Elemental analysis calculated for C32H48N4O4Ga+CH4O: C 50.72; H
6.71; N 7.17; Ga 8.92%. Found: C 50.51; H 6.68; N 7.08; Ga
9.05%.
Preparation of 67Ga-metalloprobe (5a). Radiolabeled
67
Ga-metalloprobe (5a) was synthesized by following a procedure
described earlier with slight modifications [20,22]. 67Ga was
obtained as a commercial citrate salt in water (Triad Isotopes),
converted into chloride using HCl (6N), extracted in ether
(262 mL), evaporated, and the residue was treated with
acetylacetone to obtain 67Ga(acetylacetonate)3. The radiolabeled
67
Ga-metalloprobe was obtained through a ligand exchange
reaction involving 67Ga(acetylacetonate)3 and heptadentate
Schiff-base ligand (3) dissolved in ethanol at 100uC for 40 min.
Alternatively, 67Ga-citrate was treated with HCl, loaded on a
cation-exchange cartridge (Strata), washed with water (363 mL),
and eluted with 400 mL of 98% acetone/HCl (0.02 M).

Figure 3. Characterization of 67Ga-labeled 5a in cellulo. A. Cellular accumulation of 5a in human MCF-7 cells (Pgp-) and stably transfected
MCF-7/MDR1 (Pgp+) cells. Inset: Immunodetectable levels of Pgp in plasma membrane preparations using mAb C219; MCF-7 cells (lane 1) and MCF-7/
MDR1 cells (lane 2). Arrows demarcate Pgp (170 kDa) and c-tubulin (c-t) loading control. B. Cellular accumulation of 5a in KB-3–1 cells (Pgp-) and KB8–5 (Pgp+). Shown are net uptakes at 90 min (fmol (mg protein)21 (nM0)21) using control buffer in the absence (open column) or presence (solid
column) of the MDR modulator LY335979 (1 mM). Each column represents the mean of 4 determinations; bar denotes 6SEM.
doi:10.1371/journal.pone.0109361.g003
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Figure 4. Pharmacokinetic data of 5a in WT and mdr1a/1b(2/2) mice (n = 3). In WT mice, 5a clears from the liver and does not penetrate
significantly into the brain, but shows high and stable retention in heart tissue (a Pgp negative organ) in both WT and mdr1a/1b(2/2) mice. Values
represent the mean of 3 determinations; bar denotes 6SEM.
doi:10.1371/journal.pone.0109361.g004

refinement was carried out by minimizing Sw(Fo2–Fc2)2. The nonhydrogen atoms were refined anisotropically to convergence. The
N-H hydrogens were located and refined with geometrical
restraints (Figure S1). Other hydrogen atoms were treated using
appropriate riding model (AFIX m3). Both isopropoxy groups
exhibit positional disorder (Figure S2). The disorder was resolved
by partial occupancy atoms in both chains and the relative
occupancies were refined. Two chains were located for the group
O3, C25–C27 and the occupancies were refined to 77:23%.
Furthermore, carbon atoms (C28–C30) of the second isopropoxy
substituent were also split into two groups with relative occupancies of 63:37%. These disordered groups were refined with
geometrical and displacement parameter restraints. The compound crystallizes with a molecule of H2O and a partial methanol
as a solvent of crystallization (Figure S2). Further, the occupancy
of the methanol was refined to ,19%. The solvent atoms were
also refined with geometrical and displacement parameter
restraints. X-ray crystallographic data for 4 (crystal data and
structure refinement parameters, atomic coordinates, inter-atomic
distances and angles, anisotropic displacement parameters,
hydrogen coordinates, and torsion angles) are included in Tables
S1–S6.

nate)3 and heptadentate Schiff-base precursor (3) dissolved in
ethanol at 100uC for 20 min. The reaction was followed using
thin-layer chromatography as described above. Finally, 68Gametalloprobe 5b was purified by radio-HPLC using a C-18
reversed-phase column and the same gradient eluent mixture of
ethanol and saline described above. The fraction eluting at a
retention time of 27.0 min (5b) was collected, concentrated, and
employed for bioassays.
X-ray Crystallography. Crystals suitable for X-ray crystallography were grown by dissolving 4 in refluxing methanol, slowly
bringing the solution to room temperature and then slow
evaporation of the methanol solution overnight. A single crystal
with approximate dimensions 0.3660.3360.21 mm3 was mounted
on a glass fiber in a random orientation. Preliminary examination
and data collection were performed using a Bruker Kappa Apex II
(Charge Coupled Device (CCD) Detector system) single crystal XRay diffractometer, equipped with an Oxford Cryostream LT
device. All data were collected using graphite monochromated Mo
Ka radiation (l = 0.71073 Å) from a fine focus sealed tube X-Ray
source. Preliminary unit cell constants were determined with a set
of 36 narrow frame scans. The collected data set consisted of
combinations of v and Q scan frames with a scan width of 0.5u and
counting time of 15 seconds/frame at a crystal to detector distance
of 4.0 cm. The collected frames were integrated using an
orientation matrix determined from the narrow frame scans.
Apex II and SAINT software packages were used for data
collection and data integration. Analysis of the integrated data did
not show any decay. Final cell constants were determined by
global refinement of xyz centroids of 9377 reflections from the
complete data set. Collected data were corrected for systematic
errors using SADABS [25] based on the Laue symmetry using
equivalent reflections. Structure solution and refinement were
carried out using the SHELXTL- PLUS software package. The
structure was solved by direct methods and refined successfully in
the orthorhombic space group, Pbca. Full matrix least-squares
PLOS ONE | www.plosone.org

Bioassays
Cell Culture. Rat cardiomyoblasts (H9c2) were grown in
DMEM (high glucose) supplemented with L-glutamine (2 mM)
and heat-inactivated fetal calf serum (10%). Human epidermoid
carcinoma KB-3-1 cells and colchicine-selected KB-8-5 cells were
grown as previously described [26]. Detailed growth conditions for
stably transfected MCF-7 and MCF-7/MDR1 cells have been
described earlier [27]. Briefly, KB-3-1 and KB-8-5 cells were
grown in DMEM supplemented with L-glutamine (2 mM) and
heat-inactivated fetal calf serum (10%) in the presence of 0 and
10 ng/ml colchicine, respectively. MCF-7 and MCF7/MDR1
cells were grown in DMEM supplemented with L-glutamine
4
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Table 3. Heart to Tissue Ratio of
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analyzed with a radioTLC scanner on C-18 silica gel plates using
saline/methanol (90/10) as the eluent mixture. All samples were
compared with the parental control and normalized to percentage
of parental compound for analysis.
MicroPET Imaging. Imaging was performed with 11 week
old Sprague-Dawley rats 60 min post intravenous tail-vein
injection (22,200 kBq) of HPLC-purified 68Ga-radiopharmaceutical 5b (95/5 saline/ethanol) using a Focus 220 microPET or
Inveon PET/CT scanner (Siemens Medical Solutions). For
imaging, rats were anesthetized with isoflurane via an induction
chamber and maintained with a nose cone. Following anesthesia,
the rats were secured in a supine position and placed in an acrylic
imaging tray. PET imaging consisted of a 10 min acquisition.
Image data were reconstructed into a single frame using standard
methods. For anatomical visualization, PET images were also coregistered with CT images from an Inveon PET/CT scanner.

(2 mM) and heat-inactivated fetal calf serum (10%) in the presence
of 1 mg/mL G418.
Western Blots. Pgp was detected in enriched membrane
fractions of cells with monoclonal antibody C219 (Signet
Laboratories, Inc., Dedham, MA) as described previously [28].
Cell Transport Studies. Cellular transport studies for 5a
were performed in 24-well tissue culture treated plates. Cells
(100,000/well) were plated in media and allowed to recover
overnight. Media was removed from cells and replaced with media
containing the desired concentrations of 5a (74 kBq/mL) using
control buffer either in the absence or presence of MDR
modulator LY335979 (1 mM) or 130 mM K+/valinomycin
(1 mg/mL) buffer [29]. Cells were allowed to incubate under
normal incubation conditions (37uC, 5% CO2 atmosphere) for
90 min, and then washed 36 with 4uC Solution A (phosphate
buffered saline lacking CaCl2 and MgCl2). Cells were then
extracted in 1% sodium dodecyl sulfate with 10 mM sodium
borate. Aliquots of the loading solution and 67Ga-complexes 5a
stock solutions also were obtained for standardizing cellular data
with the extracellular concentration of 5a. All cell extracts, 67Gacomplex 5a stock solutions, and loading solution samples were
assayed for c-activity in a well-type sodium iodide c-counter
(Cobra II; Packard). Protein mass was estimated by the
bicinchoninic acid analysis (Pierce Chemical Co.), using bovine
serum albumin as the protein standard. Data are reported as fmol
Ga-complex 5a (mg protein)21 (nM0)21 as previously described
[20,24], with nM0 representing the total concentration of 67Gacomplex in the extracellular buffer.
Biodistribution Studies. All animal procedures were approved by the Washington University Animal Studies Committee.
Distribution of 67Ga-complex 5a in tissues of male 4 week old
FVB wild-type (WT) and mdr1a/1b(2/2) gene-deleted (KO) mice
(Taconic) was determined as previously described [20]. Male 7
week old Sprague-Dawley rats (Harlan) were similarly used. 67GaComplex 5a dissolved in ethanol was diluted in saline/ethanol
(90/10) to the final concentration (mice: 1,480 kBq/mL; rats:
2,405 kBq/mL). All animals were anesthetized by isofluorane
inhalation and injected with radiotracer (mice: 148 kBq, 100 mL;
rats: 481 kBq, 200 mL) via bolus injection through a tail vein.
Animals were sacrificed by cervical dislocation at 5, 15 (mice) or 30
(rats), 60, and 120 min after injection (n = 3 each). Blood samples
were obtained by cardiac puncture, organs then harvested rapidly,
and all tissue samples analyzed for c-activity. Data are expressed
as the percentage injected dose (%ID) per gram of tissue (tissue
kBq (injected kBq)21 (g tissue)216100).
Metabolic Stability. For metabolic stability studies, three 10
week old Sprague Dawley rats were anesthetized by isofluorane
inhalation and injected with radiotracer 5a (81,400 kBq, 220 mL)
via bolus injection through a tail vein, sacrificed at 30 min,
60 min, 90 min and blood, urine, and tissue samples were
collected as described above. Urine samples were obtained via
either bladder puncture or external collection. Tissues were
sonicated, suspended in saline/ethanol (70/30), and extracts were
PLOS ONE | www.plosone.org

Results and Discussion
Herein we report and characterize gallium(III)-(bis(3-isopropoxy2- phenolate - benzylidene ) - N, N’-bis(2,2-dimethyl-3-amino-propyl)
ethylenediamine) (Ga-[3-isopropoxy-ENBDMPI]+), 4, a novel
hydrophobic monocationic Ga(III)-complex. Isolated as pale
yellow crystals in 30% yield, 4 was synthesized from the
condensation of a linear tetraamine and 2-hydroxy-3-isopropoxy-benzaldehyde (2, obtained via orthoformulation of 2isopropoxy phenol 1 using MgCl2 and paraformaldehyde)
followed by a ligand-exchange reaction involving 3 and
Ga(acetylacetonate)3 in methanol as shown in Fig. 1 [15,30].
The molecular structure of the isopropoxy pendant Ga(III)complex determined by x-ray diffraction (Fig. 2) demonstrates
pseudo-octahedral geometry, wherein the central metal is
surrounded by two secondary amine nitrogen atoms of the
hydrocarbon backbone, two aldimino nitrogen atoms in the
equatorial plane, and two axial phenolate oxygen atoms.
Furthermore, upon encompassing the central metal atom, the
N4O2 donor core of the ligand results in formation of four sixmembered rings and one five-membered ring involving participation of the Ga1-N2-C2-C1-N1 atoms. Additionally, Ga-O
distances average 1.9279 Å, while Ga-N distances average
2.0719 Å, consistent with formation of covalent and coordinate
bonds, respectively. While trans bond angles O1-Ga-O2, N1Ga-N3, N2-Ga-N4 average 171.6u, the cis angles centered
around O-Ga-N average 90.1u, indicating minimal distortion
from ideal octahedral geometry for complex 4. Finally, 1H
NMR and proton-decoupled 13C NMR spectra of 4 recorded in
DMSO-d6 demonstrate that the aromatic rings remain chemically equivalent upon coordination of the donor core of ligand
3, thus supporting the existence of a 2-fold symmetry for the
complex in solution. These data are in accord with other metal
complexes of related ligands [14,15,17,20–22,24,31,32], both in
solution and solid state.
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cations, permeating passively into living cells and concentrating
within the mitochondrial inner matrix in response to the driving
forces of electronegative plasma membrane and mitochondrial
transmembrane potentials [29]. This is opposed by the action of
ATP-binding-cassette (ABC) membrane transporters, such as the
multidrug resistance (MDR) P-glycoprotein (Pgp; ABCB1) and
MRP1 (ABCC1), which transport hydrophobic cationic metalcomplexes out of cells [24,33,34]. Thus, cardiomyocytes, rich in
mitochondria and lacking Pgp, sequester metal-complexes for
prolonged periods, while hepatocytes, which express Pgp along
their canalicular surface, rapidly excrete metal-complexes into the
bile and intestines. In principle, if translated in vivo, these
properties would produce rapid hepatocellular clearance of the
agent, thereby minimizing the impact of emissions arising from the
liver that could mis-register into the inferior wall of the
myocardium during imaging. Consideration of these factors
provided a platform for designing hydrophobic monocationic
gallium(III)-complexes that were simultaneously membrane potential-responsive and avidly transported by Pgp [20]. In addition,
structure-activity analysis of related metal complexes suggested
that ester and ether moieties may confer Pgp recognition
properties [35–37].
We first demonstrated the membrane potential-responsive
uptake of 67Ga(III)-complex 5a in rat H9c2 cardiomyoblasts.
Complex 5a accumulated into H9c2 cells to high levels (7456112
fmol (mg P)21 (nM0)21). Depolarizing cardiac sarcolemmal and
mitochondrial membrane potentials with 130 mM K+/20 mM
Cl2 buffer containing the potassium ionophore valinomycin
(1 mg/mL) eliminates the inward driving force for charged
complexes [33], and decreased 5a content to 155617 fmol (mg
P)21 (nM0)21, ,20% of control, indicating a significant contribution from electronegative membrane potentials driving cell uptake
of 5a.
Next, to determine whether Pgp affected cellular accumulation
of 5a, parental MCF-7 cells and a subclone stably transfected with
MDR1 Pgp were used for transport studies. Control MCF-7 cells
lack immunodetectable Pgp, whereas MCF-7/MDR1 cells express
biologically relevant Pgp levels by Western blot analysis [26,38]
(Fig. 3a). Accumulation of 67Ga-complex 5a was high in parental
MCF-7 cells and indistinguishable from zero in MCF-7/MDR1
cells (Fig. 3a). Furthermore, treatment with the potent MDR
modulator LY335979 at a concentration known to maximally
block Pgp (1 mM) [38] fully reversed the accumulation defect of 5a
in MCF-7/MDR1 cells, consistent with inhibition of Pgpmediated efflux of 5a. Importantly, LY335979 (1 mM) did not
significantly impact uptake of 5a in MCF-7 cells. Furthermore,
drug sensitive KB-3-1 cells, which lack immunodetectable Pgp,
accumulated 5a to high levels, while drug-resistant KB-8-5 cells,
which express modest Pgp levels by Western blot analysis [26,38],
showed no accumulation. As anticipated, LY335979 enhanced
cellular accumulation of 5a in the MDR KB-8-5 cells, but not
drug-sensitive KB-3-1 cells (Fig. 3b).
We then determined whether Pgp impacted the pharmacokinetics of 5a in mice in vivo. Mice possess two drug-transporting
isoforms of Pgp (mdr1a and mdr1b) [39]. Both drug-transporting
isoforms are expressed along the biliary cannalicular surface of
hepatocytes wherein the protein functions to secrete substrates into
the bile, while the mdr1a isoform is expressed on the luminal
surface of capillary endothelial cells of the brain wherein Pgp
imparts important exclusion functionality to the blood-brain
barrier [40]. Following intravenous injection in wild type (WT)
mice, 5a demonstrated fast clearance from the blood pool (%ID/
g = 1.2660.33 (5 min), 0.1060.01 (60 min)). By contrast, blood
retention 60 minutes post intravenous injection of 5a in gene-

Figure 5. Representative metabolite analysis of 67Ga-labeled
5a at 60 min post injection into a Sprague-Dawley rat (a time
point compatible with 68Ga imaging). Peaks are offset for clarity.
Note the presence of a parental compound in all tissues.
doi:10.1371/journal.pone.0109361.g005

For assessment of the Ga(III)-complex in cellulo and in vivo,
radiolabeled 67Ga- and 68Ga-complexes (5a and 5b) were
prepared with radioactive Ga(acetylacetonate)3 and ligand 3 in
ethanol at 100uC for 40 min (Fig. 1) [20,22,24]. Synthesis and
purification of the radiopharmaceutical can be accomplished in ,
1 hr, an interval of significant practical value for synthesis of PET
agents with 68Ga. Nonetheless, to perform cell tracer assays and
pharmacokinetic studies in mice and rats, 67Ga-complexes were
generated to exploit the longer half-life of 67Ga (tK = 78.2 hr),
thereby allowing cellular analysis and in vivo studies with the same
HPLC purified fraction (C-18 column; ethanol/saline gradient;
Rt = 27.0 min). Formation of radio-complexes 5a and 5b was also
monitored via radio-TLC (methanol/saline (90/10); Rf = 0.23;
radiochemical purity .95%; radiochemical yield 60%).
Mechanistic studies of cationic metal-complexes useful for MPI
have revealed that net retention of tracers in heart tissue is
determined by the opposing action of two biochemical processes
[20,33]. First, effective metal-complexes are hydrophobic mono-

Figure 6. Representative MicroPET/CT Images. Sprague-Dawley
rats (n = 3) were injected intravenously with HPLC-purified 68Ga-labeled
5b (600 mCi) and images were acquired 60 min post injection. Top
Panel, microPET images co-registered with CT; Lower Panel, microPET
images alone. Note retention of 5b in the heart (white arrow) and rapid
clearance of the tracer from the liver (white arrow head) into the
intestines, properties ideal for a myocardial perfusion imaging agent.
doi:10.1371/journal.pone.0109361.g006
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deleted mdr1a/1b(2/2) mice was 0.3460.03%ID/g, 3.4-fold
greater than WT control (Fig. 4), a result likely reflecting the
expression of Pgp in WT leukocytes [41]. Importantly, the heart, a
Pgp negative tissue, showed robust uptake and retention in both
WT (%ID/g = 12.060.7) and mdr1a/1b(2/2) (%ID/g = 14.660.6)
mice 60 min post injection of the radiotracer (Fig. 4; Tables 1
and 2). In liver, initial accumulation of 5a was comparable
between mdr1a/1b(2/2) and WT mice 5 min post injection of the
tracer (Fig. 4). However, liver clearance at 60 min was markedly
delayed in mdr1a/1b2/2 mice, showing 6-fold higher retention
compared with WT mice, consistent with Pgp-mediated biliary
secretion of the tracer. Relative to WT mice, mdr1a/1b(2/2) mice
showed an 11-fold higher retention of the 67Ga-complex in brain
parenchyma 60 minutes post injection (Fig. 4, Tables 1 and 2).
In WT mice, heart/blood and heart/liver ratios of 5a at 60 min
post injection were 130 and 1.6, respectively (Table 3). Additional
pharmacokinetic studies were conducted in WT Sprague-Dawley
male rats (n = 3) (Table S7). Pharmacokinetic profiles in rats were
found to be similar to that of WT mice, indicative of Pgp-mediated
excretion pathways. Importantly, 67Ga-complex 5a showed high
extraction and sustained retention in the heart with rapid
clearance from the blood pool and liver, yielding heart/blood
ratios of 8.4 (5 min), 50 (60 min) and 139 (120 min), and heart/
liver ratios of 0.6 (5 min), 4.2 (60 min), and 7.8 (120 min),
respectively (Table S8). Transferrin, a serum protein, has two
iron(III) binding sites with high affinity for Ga(III). Therefore,
dechelation of the radionuclide (Ga+3) from 5a could exchange
with the iron of transferrin, leading to retention of activity within
the blood pool, and tissues. For analysis, radioHPLC allows
detection of only mobile species, while radioTLC enables
assessment of both mobile and immobile radiometric species.
Therefore, we assessed samples of tissue extracts using radioTLC
for preliminary evaluation of metabolites. Importantly, radioTLC
analysis of extracts from heart, liver, blood and urine 30, 60, and
90 min post tail-vein injection of 5a in rats showed only the
existence of parental compound (Fig. 5), thus demonstrating the
high stability of the radiopharmaceutical in vivo. These results are
consistent with facile clearance of 5a from the blood pool and liver
tissue of rats.
While screening candidate radiopharmaceuticals in cellulo
identifies mechanism-based leads, many characteristics vital for
development in vivo relate to serum protein binding, pharmacokinetics, tissue retention, and overall signal-to-noise that are
difficult to predict and may adversely influence image quality.
Indeed, several promising synthetic complexes of Ga(III) have
been previously reported, but failed to generate high quality
images in vivo [22,23,42]. Thus, to begin to characterize the
properties of 5b as a MPI in vivo, microPET/CT imaging was
performed on rats following i.v. injection of HPLC-purified
complex. Analysis of the images revealed sustained retention of
5b in heart tissue and rapid clearance from the liver (Fig. 6). The
entire left ventricular wall and septum were clearly visualized on
PET images with high diagnostic quality 60 min post injection and
there was evidence of right ventricular wall visualization.
Additionally, small animal SPECT/CT images with 67Gacomplex 5a 60 min post injection were similar to the PET images
(data not shown). SUV values derived from the SPECT/CT study
showed a heart/liver ratio of 3.3, a value with excellent prospects
for further development.

ceutical. While several agents in this class have been synthesized
and reported, no prior agent has shown the favorable MPI
properties of 5b in pre-clinical models in vivo. This includes both
high contrast perfusion images of the heart combined with rapid
clearance from the liver, accomplished by a rational design
targeting Pgp transporter-mediated excretion. The design of 5b
includes aromatic scaffolds substituted with alkoxy groups, a
characteristic structural feature among several cationic metalcomplexes recognized as Pgp substrates [20,36,37,43]. Thus,
incorporation of an isopropoxy functionality into the 3-position of
the aromatic ring, which may provide resonance stabilization [44],
has significant structural consequences and indicates that properly
designed pendant moieties are capable of promoting high
myocardial uptake and rapid liver clearance of radioactive
Ga(III)-complexes. Because 68Ga is generator-produced on-site,
the ready formulation of 5b provides a promising alternative for
PET MPI, enabling point-of-care radiopharmaceutical distribution logistics temporally responsive to the urgent care needs of
individual patients. Given the biological targeting properties of 5b,
the complex also may enable PET imaging of MDR in tumors
[24,33,45], Pgp activity at the blood brain barrier in neurodegenerative diseases, such as Alzheimer’s disease and Parkinson disease
[43,46], as well as detection of mitochondrial myopathies in vivo
[47].

Supporting Information
Figure S1 Projection view (50% thermal ellipsoids) of
cationic gallium(III) complex Ga-[3-isopropoxy-ENBDMPI]+ (4) with iodide (I2) as a counter anion showing
the crystallographic numbering scheme. Solvent and
isopropyl disorders are omitted for better presentation.
(TIF)
Figure S2 Projection view (50% thermal ellipsoids) of
cationic gallium(III) complex Ga-[3-isopropoxy-ENBDMPI]+ (4) with the iodide (I2) as a counter anion
showing the crystallographic numbering scheme. While
solvent and isopropyl disorders are included, the hydrogen atoms
are excluded for a clear presentation.
(TIF)
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